<img alt="" height="1" width="1" />Revenue for Salix jumps 80 percentNews & ObserverThe company projects that winning approval as an irritable bowel syndrome treatment could mean extra annual peak sales of $2.5 billion. ...Piper Jaffray Overweight On Salix Pharmaceuticals, Has $58 Target (SLXP)<nobr>Benzinga</nobr>Salix Announces FDA Acceptance for Filing and Priority Review Designation For ...<nobr>PipelineReview.com (press release)</nobr>Xifaxan Boosts Salix Earnings - Analyst Blog<nobr>Benzinga</nobr><nobr>SunHerald.com</nobr><nobr>all 69 news articles »</nobr> |